Evidence map›Paper›PMID 30128780›Full record

ArticlePharmaceutical research2018

In Silico Prediction of Diffusion Interaction Parameter (k

Dheeraj S Tomar, Satish K Singh, Li Li, Matthew P Broulidakis, Sandeep Kumar

Abstract read
PubMed Publisher
In one paragraph

Article in Pharmaceutical research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. How can we discover developable antibody-based biotherapeutics?Frontiers in molecular biosciences · 2023
    Review
  11. Article
  12. Article
  13. Article
  14. Intrinsic physicochemical profile of marketed antibody-based biotherapeutics.Proceedings of the National Academy of Sciences of the United States of America · 2021
    Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Dheeraj S TomarBiotherapeutics Pharmaceutical Sciences Research and Development, Pfizer Inc., 700 Chesterfield Parkway West, Chesterfield, Missouri, 63017, USA.
Satish K SinghBiotherapeutics Pharmaceutical Sciences Research and Development, Pfizer Inc., 700 Chesterfield Parkway West, Chesterfield, Missouri, 63017, USA.
Li LiBiotherapeutics Pharmaceutical Sciences Research and Development, Pfizer Inc., 1 Burtt Road, Andover, Massachusetts, 01810, USA. Li.Li123@pfizer.com.
Matthew P BroulidakisBiotherapeutics Pharmaceutical Sciences Research and Development, Pfizer Inc., 1 Burtt Road, Andover, Massachusetts, 01810, USA.
Sandeep KumarBiotherapeutics Pharmaceutical Sciences Research and Development, Pfizer Inc., 700 Chesterfield Parkway West, Chesterfield, Missouri, 63017, USA. Sandeep_2.Kumar@Boehringer-Ingelheim.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo develop resource-sparing in silico approaches that aim to reduce experimental effort and material required by developability assessments (DA) of monoclonal antibody (mAb) drug candidates.

methodsA battery of standardized biophysical experiments was performed on high concentration formulations of 16 drug product development stage mAbs using a platform buffer. Full-length molecular models of these mAbs were also generated via molecular modeling. These models were used to computationally estimate molecular descriptors of these 16 mAbs. Pairwise and multi-parameter correlations among experimentally measured biophysical attributes and calculated molecular descriptors were obtained via statistical analyses.

resultsDiffusion interaction parameter (k

conclusionsDiffusion interaction parameter (k

Indexed as

Computer SimulationAntibodies, MonoclonalDiffusionHydrogen-Ion ConcentrationIsoelectric PointModels, MolecularMolecular WeightProtein StabilityRheologySolubilitySolutionsTemperatureViscosityAntibodies, MonoclonalSolutionsbiopharmaceutical informaticsdiffusion interaction parameterhigh concentrationmolecular modelingmonoclonal antibody

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.